Recombinant adeno-associated viral vectors have been used in several clinical trials for several advantages. The rAAVs have been also a popular tool for gene-editing requirements.
Despite the inception of modern technologies, the latest tools and innovations, various kinds of challenges haven’t gone past. In fact, a good number of companies find it difficult to produce these vectors in high-quality and large quantities. Nonetheless, there are certainly reliable and reputed companies that offer clinical-grade AAV for their typical applications.
What are the upstream methods? What are the starting materials? A curious mind would want to learn the answers to these questions and find out what’s possible on a niche platform.
In a common scene, one can find impurities in clinical trial AAV, such as defective particles, illegitimate DNA, and residual proteins. Upon analysis, it was discovered that these impurities were independent of common behavior and most of them were caused due to the individual platforms where AAVs are manufactured.
Prior to the approval of AAVs for clinical experiments or trials, it’s always important to bring a sample and check the potential value. Perhaps, you can check in on with the experts in the sector and discuss what’s needed.
Several companies offer automated solutions to these problems, which may or may not work out eventually. Nevertheless, the companies with dedicated R&D divisions and experienced scientists will not let that happen to their customers. Moreover, you can have clear communication with these experts and convey your doubts.
